| Name | Title | Contact Details |
|---|
The Transverse Myelitis is a Redmond, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.
The Abbott Union Free School District provides programs especially designed for children with special needs.
National Genetics Institute is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. National Genetics Institute is based in Los Angeles, CA. You can find more information on National Genetics Institute at www.ngi.com
FinPay, LLC provides Patient Financial Management Solutions to assist healthcare providers in their strategy to manage the $400 billion in patient out-of-pocket medical expenses that has caused a massive spike in bad debt and lost revenue to providers nationwide. The continuing shift of financial responsibility to the patient for the cost of healthcare has forced healthcare providers to rethink their Patient Financial Management strategy. FinPay`s solution provides: 1. Financial Clearance Policies that target and segment patients that pose a high financial risk to the provider and customized work flow for these high risk patients. 2. Patient engagement at the point of care to educate patients about their financial obligations and to manage patient expectations on the billing and claims process. 3. An automated payments platform that offers patients more alternatives for payment. Our platform automates patient installment plans and consumer non-recourse medical loans, in addition to processing of traditional payment methods like credit/debit/HSA cards and checks. 4. Compliance tools so providers are compliant with federal and state consumer protection laws. FinPay`s mission is to provide a patient financial experience that mirrors the high quality clinical care experienced by most patients. At the core of our programs is a change in conversation at the point-of-care. A conversation that starts with helping the patient understand their financial obligations. A conversation that simplifies the process by giving patients what they want, more options to fit their household budget and more transparency. A conversation that results in facilitating a payment program they can afford, and more importantly, one they have the best chance of actually paying.